Skip to content
  • People
  • Pipeline
  • Publications
  • News
Menu
  • People
  • Pipeline
  • Publications
  • News
  • People
  • Pipeline
  • Publications
  • News
  • Contact us
Menu
  • People
  • Pipeline
  • Publications
  • News
  • Contact us
Contact

News

Read all about our latest news.
Loading...
January 9, 2023

Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives

Read more
October 19, 2022

Monument Therapeutics featured in Drug Discovery World magazine, discussing the rise of digital biomarkers in neuroscience drug development

Read more
August 2, 2022

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference

Read more
June 13, 2022

Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation

Read more
June 7, 2022

We are attending the BIO Conference: join us at two exciting sessions

Read more
May 2, 2022

Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)

Read more
April 26, 2022

Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!

Read more
April 11, 2022

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA

Read more
March 15, 2022

Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference

Read more
March 15, 2022

Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference

Read more
December 14, 2021

Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic

Read more
September 21, 2021

Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study

Read more
September 13, 2021

New Interview in Scrip

Read more
August 12, 2021

Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board

Read more
August 3, 2021

Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director

Read more
July 1, 2021

Digital brain biomarker company Monument Therapeutics raises £2.6 million

Read more
June 29, 2017

Richard Bungay Joins the Board as a Director

Read more
Loading...
January 9, 2023

Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives

Read more
October 19, 2022

Monument Therapeutics featured in Drug Discovery World magazine, discussing the rise of digital biomarkers in neuroscience drug development

Read more
August 2, 2022

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference

Read more
1 2 … 6 Next »

Contact Us

We believe that neuroscience will be in the next decade what oncology has been in the last.

Get in touch
MT LOGO WHITE PNG-01
info@monumenttx.com
© Copyright 2023  |  Privacy Policy & Terms of Use